达巴万星在体外以及在金黄色葡萄球菌所致实验性心内膜炎兔模型中的活性，该金黄色葡萄球菌对万古霉素和替考拉宁的敏感性降低或未降低。
Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.
作者信息
Lefort Agnès, Pavie Juliette, Garry Louis, Chau Françoise, Fantin Bruno
机构信息
Faculté de Médecine Xavier Bichat and University Paris VII, 75018 Paris, France.
出版信息
Antimicrob Agents Chemother. 2004 Mar;48(3):1061-4. doi: 10.1128/AAC.48.3.1061-1064.2004.
Abstract
For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.
摘要
对于兔心内膜炎的治疗，达巴万星每日给药一次（10毫克/千克体重，共4天）或单次给予40毫克/千克剂量，对金黄色葡萄球菌均有活性，无论该菌对糖肽类药物的敏感性是否降低，从其良好的体外活性来看这是预期的结果，即使在添加90%血清的肉汤中，鉴于其较长的消除半衰期也是如此。
相似文献
1
Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.达巴万星在体外以及在金黄色葡萄球菌所致实验性心内膜炎兔模型中的活性，该金黄色葡萄球菌对万古霉素和替考拉宁的敏感性降低或未降低。
Antimicrob Agents Chemother. 2004 Mar;48(3):1061-4. doi: 10.1128/AAC.48.3.1061-1064.2004.
2
Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.糖肽类药物在兔心内膜炎模型中对金黄色葡萄球菌感染的活性：最低抑菌浓度不能预测体内疗效。
Antimicrob Agents Chemother. 2005 Feb;49(2):857-9. doi: 10.1128/AAC.49.2.857-859.2005.
3
Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.糖肽类药物敏感性降低对万古霉素和替考拉宁在实验性心内膜炎中抗金黄色葡萄球菌活性的影响。
Antimicrob Agents Chemother. 2003 Jun;47(6):2018-21. doi: 10.1128/AAC.47.6.2018-2021.2003.
4
Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.
J Chemother. 2016 Oct;28(5):446-9. doi: 10.1179/1973947815Y.0000000031. Epub 2016 May 5.
5
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.达托霉素与替考拉宁和万古霉素治疗实验性金黄色葡萄球菌心内膜炎的比较。
Antimicrob Agents Chemother. 1990 Nov;34(11):2081-5. doi: 10.1128/AAC.34.11.2081.
6
Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome.苯唑西林和糖肽类药物对感染性心内膜炎患者金黄色葡萄球菌的杀菌活性：寻找耐药性与结局的关系。
Ann Clin Microbiol Antimicrob. 2011 Jun 9;10:26. doi: 10.1186/1476-0711-10-26.
7
Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.金黄色葡萄球菌心内膜炎治疗期间替考拉宁耐药性的出现。
J Infect Dis. 1990 Jul;162(1):103-8. doi: 10.1093/infdis/162.1.103.
8
Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.替考拉宁与万古霉素治疗耐甲氧西林表皮葡萄球菌所致实验性心内膜炎的比较。
J Infect Dis. 1986 Jul;154(1):69-75. doi: 10.1093/infdis/154.1.69.
9
10
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.LY333328治疗实验性耐甲氧西林金黄色葡萄球菌心内膜炎的疗效。
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
引用本文的文献
1
A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.达巴万星作为感染性心内膜炎序贯治疗药物疗效的系统评价。
Infection. 2025 Feb;53(1):15-23. doi: 10.1007/s15010-024-02393-9. Epub 2024 Sep 26.
2
Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.达巴万星在实际应用中的治疗药物监测：两年经验
Antibiotics (Basel). 2023 Dec 24;13(1):20. doi: 10.3390/antibiotics13010020.
3
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.感染性心内膜炎的新型抗菌药物及新治疗策略：需加以捍卫的武器
J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693.
4
Use of dalbavancin in infective endocarditis: a case series.达巴万星在感染性心内膜炎中的应用：病例系列
JAC Antimicrob Resist. 2021 Aug 12;3(3):dlab099. doi: 10.1093/jacamr/dlab099. eCollection 2021 Sep.
5
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.糖肽类抗生素在革兰阳性感染中的应用：比较综述。
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
6
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.达巴万星：一种新型脂糖肽类抗生素，对革兰氏阳性感染具有扩展作用。
Infect Dis Ther. 2015 Sep;4(3):245-58. doi: 10.1007/s40121-015-0077-7. Epub 2015 Sep 4.
7
Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.达巴万星：治疗急性细菌性皮肤和皮肤结构感染的综述。
Drugs. 2015 Jul;75(11):1281-91. doi: 10.1007/s40265-015-0430-x.
8
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.金黄色葡萄球菌中万古霉素敏感性降低，包括万古霉素中介和异质性万古霉素中介菌株：耐药机制、实验室检测及临床意义。
Clin Microbiol Rev. 2010 Jan;23(1):99-139. doi: 10.1128/CMR.00042-09.
9
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.达巴万星对体外炭疽杆菌和小鼠吸入性炭疽模型的活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. doi: 10.1128/AAC.00820-09. Epub 2010 Jan 4.
10
本文引用的文献
1
Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.糖肽类药物敏感性降低对万古霉素和替考拉宁在实验性心内膜炎中抗金黄色葡萄球菌活性的影响。
Antimicrob Agents Chemother. 2003 Jun;47(6):2018-21. doi: 10.1128/AAC.47.6.2018-2021.2003.
2
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.新型糖肽类抗菌剂BI 397的体外评价
J Chemother. 2001 Jun;13(3):244-54. doi: 10.1179/joc.2001.13.3.244.
3
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.新型半合成糖肽抗生素BI 397的体外和体内抗菌活性
J Antimicrob Chemother. 1999 Aug;44(2):179-92. doi: 10.1093/jac/44.2.179.
4
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.LY333328在耐万古霉素粪肠球菌所致实验性心内膜炎中的活性与扩散
Antimicrob Agents Chemother. 1999 Jan;43(1):115-20. doi: 10.1128/AAC.43.1.115.
5
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.法国一家医院分离出首例万古霉素中介金黄色葡萄球菌临床菌株。
Lancet. 1998 Apr 18;351(9110):1212. doi: 10.1016/s0140-6736(05)79166-2.
6
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.对万古霉素敏感性降低的金黄色葡萄球菌——美国，1997年
MMWR Morb Mortal Wkly Rep. 1997 Aug 22;46(33):765-6.
7
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.对万古霉素敏感性降低的耐甲氧西林金黄色葡萄球菌临床菌株。
J Antimicrob Chemother. 1997 Jul;40(1):135-6. doi: 10.1093/jac/40.1.135.
8
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
Zotero 插件